Authors :
ANZA. A. S; SHIFANA. S; ANEETA TOMS; Dr. G JELADHARAN
Volume/Issue :
Volume 7 - 2022, Issue 6 - June
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3yocqYD
DOI :
https://doi.org/10.5281/zenodo.6809011
Abstract :
Although the most recorded adverse events
of COVID-19 vaccination includes local injection site
effects like pain, redness or swelling, headache, fever
and chills, fatigue, myalgia and arthralgia, the rare
neurological side effects such as encephalitis has been
reported. We conducted a thorough search through
PubMed and applicable literatures were selected. All
the reported cases of encephalitis in our study were
announced after AstraZeneca (13), Pfizer-BioNTech (5),
Moderna (3), Sinopharm (2) and Sputnik V (1)
vaccination, involving 15 females, 8 males and 1 transmale, ranging in age between 16 and 77 years. The
study includes cases of 1 pediatric, 9 young adults and
14 older adults. Most of the patients showed a symptom
onset that started within a week post vaccination where
15 patients developed symptoms following the first dose,
5 patients following the second dose and 1 patient
following the booster dose. Fever and headache were the
most frequent presenting symptom. In most of the cases,
CSF analysis, EEG and other neuroimaging reports
showed abnormality. Most of the patients were treated
with IV methylprednisolone and some of the patients
had undergone plasmapheresis. Majority of the patients
showed positive response to the treatment and their
clinical conditions improved. Out of 24 patients, 2 had
died.
Keywords :
COVID-19, corona virus, vaccination, encephalitis.
Although the most recorded adverse events
of COVID-19 vaccination includes local injection site
effects like pain, redness or swelling, headache, fever
and chills, fatigue, myalgia and arthralgia, the rare
neurological side effects such as encephalitis has been
reported. We conducted a thorough search through
PubMed and applicable literatures were selected. All
the reported cases of encephalitis in our study were
announced after AstraZeneca (13), Pfizer-BioNTech (5),
Moderna (3), Sinopharm (2) and Sputnik V (1)
vaccination, involving 15 females, 8 males and 1 transmale, ranging in age between 16 and 77 years. The
study includes cases of 1 pediatric, 9 young adults and
14 older adults. Most of the patients showed a symptom
onset that started within a week post vaccination where
15 patients developed symptoms following the first dose,
5 patients following the second dose and 1 patient
following the booster dose. Fever and headache were the
most frequent presenting symptom. In most of the cases,
CSF analysis, EEG and other neuroimaging reports
showed abnormality. Most of the patients were treated
with IV methylprednisolone and some of the patients
had undergone plasmapheresis. Majority of the patients
showed positive response to the treatment and their
clinical conditions improved. Out of 24 patients, 2 had
died.
Keywords :
COVID-19, corona virus, vaccination, encephalitis.
